Risperidone versus typical antipsychotic medication for schizophrenia

Gilbody, Simon; Bagnall, A; Duggan, Lorna; Tuunainen, Arja

doi:10.1002/14651858.cd000440

Cited by 117 publications

(51 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this apparent advantage may be because the newer agents have been compared with inappropriately high doses of the older comparator drugs. 22 Safer reported eight trials sponsored by three different drug companies which compared newer second-generation neuroleptic agents to a fixed high dose (20 mg/day) of haloperidol. Predictably, patients using the new agents had fewer extrapyramidal side effects.…”

Section: Using Inappropriate 'Active' Comparatorsmentioning

confidence: 99%

Comparator bias: why comparisons must address genuine uncertainties

Mann

Djulbegoviĉ

2013

J R Soc Med

View full text Add to dashboard Cite

Section: Using Inappropriate 'Active' Comparatorsmentioning

confidence: 99%

Comparator bias: why comparisons must address genuine uncertainties

Mann

Djulbegoviĉ

2013

J R Soc Med

View full text Add to dashboard Cite

“…Next, the reference lists of review articles and meta-analyses were examined to identify possible studies not found during the online search. For example, we checked the reference lists of the latest systematic reviews carried out by the Cochrane Collaboration which involved AAs available in the market [12][13][14][15][16][17][18][19] .…”

Section: Search Strategiesmentioning

confidence: 99%

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics

Oliveira

Nunes

Coutinho

et al. 2009

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Comparisons of the effi cacy of haloperidol and risperidone in improving negative symptoms have appeared in several publications. [23][24][25][26] Judging from those reports, the effi cacy of risperidone versus haloperidol in patients with schizophrenic disorders with depressive symptoms is an unresolved question. In our study, the comparison included another factor, sertraline, an antidepressant extending the effect of haloperidol on affective symptoms, but concurrently represented a certain risk for potential drug interactions and possible worsening of schizophrenic symptoms.…”

Section: Discussionmentioning

confidence: 99%

Combination therapy or monotherapy for the depressed type of schizoaffective disorder

Izáková

Andre²,

Halaris

2009

NDT

View full text Add to dashboard Cite

Several studies have demonstrated the effectiveness of adjunctive antidepressant drug therapy to improve the depressive or negative symptoms of schizoaffective disorder, however, monotherapy with atypical antipsychotics may be advantageous. We compared the effi cacy and safety of risperidone monotherapy versus combination therapy of haloperidol with sertaline for the acute treatment of schizoaffective disorder, depressed type. This is an open label study of 52 female inpatients randomly assigned to risperidone alone (N = 26) or haloperidol in combination with sertraline (N = 26) for 12 weeks. The mean daily doses of medications were: risperidone: 3.75-3.29 mg/day, haloperidol: 5.35-4.15 mg/day, sertraline: 65.39-133.82 mg/day. Effi cacy was measured using clinical rating scales of treatment, safety, and tolerability. Risperidone patients showed statistically signifi cant greater improvement than haloperidol-sertraline patients on effi cacy measures including Positive and Negative Syndrome Scale and Clinical Global Impressions rating. A higher number of risperidone patients dropped out of the study early. Fewer adverse events and lesser need for concomitant medications occurred in patients on risperidone. The risperidone group showed better psychological, social and occupational functioning (Global Assessment of Functioning) and higher quality of life (Heinrich's Quality of Life Scale). Risperidone has higher antipsychotic effi cacy and tolerability compared with haloperidol-sertraline combination for the acute treatment of schizoaffective disorder, depressed type. Both treatments were comparable in terms of antidepressant effi cacy.

show abstract

Risperidone versus typical antipsychotic medication for schizophrenia

Cited by 117 publications

References 74 publications

Comparator bias: why comparisons must address genuine uncertainties

Comparator bias: why comparisons must address genuine uncertainties

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics

Combination therapy or monotherapy for the depressed type of schizoaffective disorder

Contact Info

Product

Resources

About